AR052498A1 - Vacuna - Google Patents

Vacuna

Info

Publication number
AR052498A1
AR052498A1 ARP060100773A ARP060100773A AR052498A1 AR 052498 A1 AR052498 A1 AR 052498A1 AR P060100773 A ARP060100773 A AR P060100773A AR P060100773 A ARP060100773 A AR P060100773A AR 052498 A1 AR052498 A1 AR 052498A1
Authority
AR
Argentina
Prior art keywords
vzv
adjuvant
vaccine
postherpeptic
mpl
Prior art date
Application number
ARP060100773A
Other languages
English (en)
Spanish (es)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34430592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR052498(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of AR052498A1 publication Critical patent/AR052498A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP060100773A 2005-03-03 2006-03-01 Vacuna AR052498A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0504436.7A GB0504436D0 (en) 2005-03-03 2005-03-03 Vaccine

Publications (1)

Publication Number Publication Date
AR052498A1 true AR052498A1 (es) 2007-03-21

Family

ID=34430592

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP060100773A AR052498A1 (es) 2005-03-03 2006-03-01 Vacuna
ARP170100008A AR107285A2 (es) 2005-03-03 2017-01-03 Vacuna

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170100008A AR107285A2 (es) 2005-03-03 2017-01-03 Vacuna

Country Status (36)

Country Link
US (3) US20080171079A1 (enExample)
EP (4) EP2281830B1 (enExample)
JP (2) JP5420842B2 (enExample)
KR (2) KR101357204B1 (enExample)
CN (2) CN103028113B (enExample)
AR (2) AR052498A1 (enExample)
AU (1) AU2006222225B2 (enExample)
BE (1) BE2018C035I2 (enExample)
BR (1) BRPI0607840B1 (enExample)
CA (2) CA2882255C (enExample)
CY (5) CY1116108T1 (enExample)
DK (4) DK2281830T3 (enExample)
EA (1) EA011884B1 (enExample)
ES (4) ES2675055T3 (enExample)
FR (1) FR18C1040I2 (enExample)
GB (1) GB0504436D0 (enExample)
HR (4) HRP20150142T1 (enExample)
HU (4) HUE038468T2 (enExample)
IL (1) IL185442A (enExample)
LT (4) LT2281830T (enExample)
LU (1) LUC00087I2 (enExample)
MA (1) MA29714B1 (enExample)
MX (2) MX346865B (enExample)
MY (1) MY148464A (enExample)
NL (1) NL300951I2 (enExample)
NO (2) NO341841B1 (enExample)
NZ (1) NZ561075A (enExample)
PE (2) PE20061287A1 (enExample)
PL (4) PL1858917T3 (enExample)
PT (4) PT2301955T (enExample)
SI (4) SI1858917T1 (enExample)
TR (2) TR201809393T4 (enExample)
TW (1) TWI403517B (enExample)
UA (1) UA94900C2 (enExample)
WO (1) WO2006094756A2 (enExample)
ZA (1) ZA200707144B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2175882A4 (en) * 2007-07-19 2011-11-30 Novavax Inc VARICELLA ZOSTER VIRUS VIRUS LIKE PARTICLES (VLP) AND ANTIGENE
FR2952825B1 (fr) 2009-11-24 2012-05-25 Goaster Jacqueline Le Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2
JP5940064B2 (ja) 2010-07-06 2016-06-29 ノバルティス アーゲー 低用量のｒｎａを用いた大型哺乳動物の免疫化
RS54489B1 (sr) 2010-07-06 2016-06-30 Glaxosmithkline Biologicals Sa Lipozomi sa lipidima koji imaju poboljšanu pka vrednost za oslobađanje rnk
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
SMT202200311T1 (it) 2010-08-31 2022-09-14 Glaxosmithkline Biologicals Sa Liposomi pegilati per somministrare rna codificante un immunogene
EP3520813B1 (en) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
JP2015091794A (ja) * 2013-10-03 2015-05-14 日東電工株式会社 注射ワクチン組成物
JP6499420B2 (ja) * 2014-11-13 2019-04-10 公益財団法人ヒューマンサイエンス振興財団 ワクチン及び感染防御キット
BE1022523B1 (fr) * 2014-12-18 2016-05-20 Glaxosmithkline Biologicals Sa Vaccination
EP3233118A1 (en) * 2014-12-18 2017-10-25 GlaxoSmithKline Biologicals S.A. Vaccination
JP6925688B2 (ja) * 2015-10-22 2021-08-25 モデルナティーエックス， インコーポレイテッド 水痘帯状疱疹ウイルス（ｖｚｖ）のための核酸ワクチン
MA47016A (fr) 2015-10-22 2018-08-29 Modernatx Inc Vaccins contre les virus respiratoires
SG10202012205XA (en) 2015-11-06 2021-01-28 Adjuvance Technologies Inc Triterpene saponin analogues
US10925958B2 (en) 2016-11-11 2021-02-23 Modernatx, Inc. Influenza vaccine
WO2018097642A1 (ko) * 2016-11-25 2018-05-31 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스 백신
KR102028463B1 (ko) * 2016-11-25 2019-10-04 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스 백신
CN107022559A (zh) * 2016-12-08 2017-08-08 长春祈健生物制品有限公司 一种水痘‑带状疱疹病毒糖蛋白e胞外区蛋白的制备方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CA3048608C (en) * 2016-12-26 2021-11-23 Mogam Institute For Biomedical Research Herpes zoster vaccine composition
CN108727503A (zh) * 2017-04-18 2018-11-02 武汉博沃生物科技有限公司 VZV重组gE-鞭毛素融合蛋白及其制备方法和应用
EP3615039A4 (en) * 2017-04-25 2021-01-13 Adjuvance Technologies, Inc. TRITERPENIC SAPONIN ANALOGUES
IL292991A (en) 2017-04-25 2022-07-01 Adjuvance Tech Inc Triterpene saponin analogs
US20210187098A1 (en) * 2017-04-28 2021-06-24 Glaxosmithkline Biologicals Sa Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
FR3066920A1 (fr) 2017-05-30 2018-12-07 Glaxosmithkline Biologicals S.A. Nouveaux procedes de fabrication d'un adjuvant
AU2018350887A1 (en) 2017-10-16 2020-03-05 Adjuvance Technologies, Inc. Triterpene saponin analogues
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
CN108315344A (zh) * 2018-02-14 2018-07-24 武汉博沃生物科技有限公司 Vzv糖蛋白e基因表达载体及其重组酵母菌株与应用
KR102337922B1 (ko) 2018-04-19 2021-12-09 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
KR20190121956A (ko) 2018-04-19 2019-10-29 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
MY195490A (en) * 2018-05-23 2023-01-26 Mogam Inst Biomedical Res Antigen Variant Of Varicella Zoster Virus And Use Thereof
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
CN108992667A (zh) * 2018-08-09 2018-12-14 安徽智飞龙科马生物制药有限公司 一种带状疱疹疫苗及其制备方法、应用
KR102270048B1 (ko) * 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
CN113164586B (zh) * 2018-09-27 2024-04-16 武汉博沃生物科技有限公司 免疫组合物及其制备方法与应用
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
CN109602901B (zh) * 2019-01-08 2022-05-27 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
CN112142828B (zh) * 2019-06-28 2022-02-01 怡道生物科技(苏州)有限公司 一种gE基因及表达该基因的载体
CN115177724A (zh) * 2019-06-28 2022-10-14 怡道生物科技(苏州)有限公司 一种重组带状疱疹疫苗组合物及其用途
CN112972671B (zh) * 2019-12-13 2024-04-19 远大赛威信生命科学(南京)有限公司 药物组合物及其用途
CA3173743A1 (en) * 2020-02-28 2021-09-02 Celltrion Inc. Varicella zoster virus fusion protein and immunogenic composition comprising same
CN115768892A (zh) 2020-03-09 2023-03-07 戴纳瓦克斯技术公司 包含tlr9激动剂的带状疱疹疫苗
MX2023001586A (es) 2020-08-07 2023-05-03 Access To Advanced Health Inst Saponinas purificadas y proceso cromatografico para purificacion de las mismas.
WO2022055176A1 (ko) * 2020-09-11 2022-03-17 주식회사 유바이오로직스 수두 또는 대상포진 백신 조성물 및 이를 이용하는 방법
RU2750818C1 (ru) * 2020-11-19 2021-07-05 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова Вирусный штамм для получения аттенуированной живой культуральной вакцины для профилактики и лечения опоясывающего герпеса для взрослого населения
WO2023056912A1 (en) * 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for vzv
US20240366754A1 (en) 2021-10-15 2024-11-07 BioNTech SE Pharmaceutical compositions for delivery of viral antigens and related methods
JP2024541466A (ja) 2021-11-24 2024-11-08 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 水痘帯状疱疹ウイルス免疫原組成物及びその使用
CN116327912A (zh) * 2021-12-23 2023-06-27 上海泽润生物科技有限公司 带状疱疹疫苗组合物
CN116350770B (zh) * 2021-12-28 2024-07-12 成都迈科康生物科技有限公司 一种带状疱疹疫苗制剂及其制备方法
EP4558170A1 (en) 2022-07-19 2025-05-28 GlaxoSmithKline Biologicals S.A. Continuous process for vaccine production
CN116655748B (zh) * 2023-02-28 2024-07-26 易慧生物技术(上海)有限公司 一种截短型水痘-带状疱疹病毒gE蛋白及其应用
CN118240844B (zh) * 2024-05-27 2024-12-13 北京悦康科创医药科技股份有限公司 带状疱疹mRNA疫苗及其制备方法和应用
WO2026006687A1 (en) * 2024-06-28 2026-01-02 Orbital Therapeutics, Inc. Circular rna compositions and uses thereof for diseases caused by varicella-zoster virus
CN120081913B (zh) * 2025-05-08 2025-08-12 江苏华诺泰生物医药科技有限公司 一种重组带状疱疹病毒原液的纯化方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5341202B2 (enExample) * 1974-03-12 1978-11-01
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK0405867T3 (da) 1989-06-27 1995-05-22 Smithkline Beecham Biolog Hidtil ukendte forbindelser
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
WO1994002596A1 (en) * 1992-07-17 1994-02-03 Merck & Co., Inc. Method for preventing zoster or alleviating varicella related post-herpetic neuralgia
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
US5976552A (en) * 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
JP4373495B2 (ja) * 1995-03-23 2009-11-25 イミュネックス・コーポレーション Ｉｌ−１７受容体
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
KR0177323B1 (ko) * 1996-02-16 1999-04-01 성재갑 바이러스 백신 생산에 유용한 사람 이배체 폐세포 및 이를 이용한 수두 백신의 제조방법
PL190237B1 (pl) 1997-04-01 2005-11-30 Corixa Corp Kompozycja adiuwantowa, szczepionka, sposób wytwarzania kompozycji adiuwantowej oraz zastosowanie
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9901254D0 (en) * 1999-01-20 1999-03-10 Smithkline Beecham Biolog Vaccines
BR0114786A (pt) * 2000-10-18 2003-08-12 Glaxosmithkline Biolog Sa Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine

Also Published As

Publication number Publication date
EP1858917B1 (en) 2014-12-24
FR18C1040I2 (fr) 2019-09-20
TWI403517B (zh) 2013-08-01
CY2018025I1 (el) 2018-12-12
WO2006094756A2 (en) 2006-09-14
US20110045059A1 (en) 2011-02-24
NL300951I1 (nl) 2018-09-26
JP5840167B2 (ja) 2016-01-06
DK1858917T3 (da) 2015-02-02
SI2281830T1 (sl) 2017-03-31
CY1121211T1 (el) 2020-05-29
US7939084B1 (en) 2011-05-10
CY1120347T1 (el) 2018-12-12
FR18C1040I1 (fr) 2018-11-02
CA2882255C (en) 2018-03-27
BE2018C035I2 (enExample) 2025-09-05
TR201809397T4 (tr) 2018-07-23
UA94900C2 (uk) 2011-06-25
TR201809393T4 (tr) 2018-07-23
CY1116108T1 (el) 2017-02-08
PL2281830T3 (pl) 2017-06-30
ZA200707144B (en) 2009-11-25
CN103028113A (zh) 2013-04-10
SI1858917T1 (sl) 2015-03-31
EP2281830A2 (en) 2011-02-09
ES2532803T3 (es) 2015-03-31
NO20074392L (no) 2007-11-27
SI2281831T1 (en) 2018-07-31
LT2301955T (lt) 2018-07-10
EA011884B1 (ru) 2009-06-30
JP5420842B2 (ja) 2014-02-19
IL185442A0 (en) 2008-01-06
KR20140006115A (ko) 2014-01-15
EP2301955A3 (en) 2011-11-16
IL185442A (en) 2013-07-31
LUC00087I2 (enExample) 2018-11-26
KR101357204B1 (ko) 2014-02-06
BRPI0607840A2 (pt) 2009-06-13
EP1858917B8 (en) 2015-05-06
PE20100658A1 (es) 2010-10-23
CN101189254B (zh) 2013-05-22
AU2006222225A1 (en) 2006-09-14
NO2018033I1 (no) 2018-09-20
PT1858917E (pt) 2015-02-24
JP2013144710A (ja) 2013-07-25
AR107285A2 (es) 2018-04-18
MX2007010626A (es) 2007-10-16
CA2600905A1 (en) 2006-09-14
ES2675055T3 (es) 2018-07-06
CN103028113B (zh) 2015-05-20
KR20070110413A (ko) 2007-11-16
HRP20180989T1 (hr) 2018-08-10
EP2281831B1 (en) 2018-04-18
HUE038467T2 (hu) 2018-10-29
HUS1800038I1 (hu) 2018-10-29
PT2281831T (pt) 2018-06-15
PL1858917T3 (pl) 2015-05-29
EA200701632A1 (ru) 2008-02-28
GB0504436D0 (en) 2005-04-06
BRPI0607840B1 (pt) 2021-06-29
PT2281830T (pt) 2017-02-24
AU2006222225B2 (en) 2012-08-16
US20110104260A1 (en) 2011-05-05
CY2018025I2 (el) 2018-12-12
LT2281830T (lt) 2017-02-10
EP2281830B1 (en) 2016-12-21
DK2301955T3 (en) 2018-06-14
PT2301955T (pt) 2018-06-18
HRP20170081T1 (hr) 2017-03-24
TW200643028A (en) 2006-12-16
EP1858917A2 (en) 2007-11-28
NO341841B1 (no) 2018-02-05
HRP20180988T1 (hr) 2018-08-10
CA2600905C (en) 2015-05-05
LTC2281831I2 (lt) 2020-08-25
ES2675054T3 (es) 2018-07-06
NZ561075A (en) 2009-06-26
MY148464A (en) 2013-04-30
LTPA2018012I1 (lt) 2018-11-12
NL300951I2 (nl) 2020-08-31
EP2281831A2 (en) 2011-02-09
EP2281831A3 (en) 2011-11-16
PL2281831T3 (pl) 2018-08-31
HUE038468T2 (hu) 2018-10-29
HK1111427A1 (en) 2008-08-08
US20080171079A1 (en) 2008-07-17
JP2008531637A (ja) 2008-08-14
HUE032544T2 (en) 2017-10-30
DK2281830T3 (en) 2017-03-20
MX346865B (es) 2017-04-04
SI2301955T1 (en) 2018-07-31
LT2281831T (lt) 2018-07-10
DK2281831T3 (en) 2018-06-14
EP2301955A2 (en) 2011-03-30
HRP20150142T1 (hr) 2015-05-22
WO2006094756A3 (en) 2007-02-15
MA29714B1 (fr) 2008-09-01
ES2618037T3 (es) 2017-06-20
CA2882255A1 (en) 2006-09-14
CN101189254A (zh) 2008-05-28
EP2301955B1 (en) 2018-04-18
PL2301955T3 (pl) 2018-08-31
PE20061287A1 (es) 2006-12-07
CY1118629T1 (el) 2017-07-12
EP2281830A3 (en) 2012-01-25

Similar Documents

Publication Publication Date Title
AR052498A1 (es) Vacuna
BRPI0619795B8 (pt) composição imunogênica, composição adjuvante, e, uso de uma composição imunogênica e um adjuvante
BRPI0621181A8 (pt) Substâncias imunogênicas que compreendem um adjuvante a base de ácido poliinosínico - ácido policitidílico
BRPI1013780B8 (pt) Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
CL2007001698A1 (es) Composicion inmunogenica que comprende los lipooligosacaridos meningococicos (los) de inmunotipos l2 y l3 de cepas neissericas; composicion de vacuna que la comprende; procedimiento de preparacion; y su uso para la prevencion o tratamiento de enfermedades causadas por uno o mas serogrupos de n. meningitidis.
CU23759A3 (es) Composiciones inmunogénicas
MX2009003325A (es) Vacuna que comprende un adyuvante de emulsion de aceite en agua.
AR040204A1 (es) Composicion de vacuna meningococica multivalente
NO20092021L (no) Faste former inneholdende 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluor-fenylamino)-9H-purin-2-ylamino]-cykloheksan-1-ol, sammensetninger derav og anvendelse derav
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
UY30948A1 (es) Uso, en composicion de ligante hidraulico, de carbonato de calcio molido en seco con copolimero del acido (met) acrilico + funcion alcoxi / hidroxi polialquilenglicol
BR112023019301A2 (pt) Formulações de vacina de coronavírus
AR108718A2 (es) Composición
AR063460A1 (es) Composicion solida para el tratamiento de agua
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
GB0703976D0 (en) Liposome preparation
WO2007028985A3 (en) Adjuvanted vaccine
CL2008002485A1 (es) Uso de gestagenos en combinacion con (6s)-5-metiltetrahidrofolato para el tratamiento de la endometriosis con reduccion de los efectos colaterales terapeuticos; procedimiento de preparacion de una composicion farmaceutica que comprende a dichos compuestos.
CL2008001102A1 (es) Compuestos derivados de [1,2,3]triazolo [4,5-b]piridina-carboxamidas, inhibidores de monoacilglicerol lipasa (mgl); procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso en el tratamiento de dolores agudos o cronicos, vertigos, vomitos, nauseas, sindrome metabolico, dislipidemia, entre otros.
UA91203C2 (ru) Новая фармацевтическая композиция, применимая для вакцин
HK1105354A (en) Immunogenic composition for use in vaccination against staphylococcei
HK1106146A (en) Immunogenic composition for use in vaccination against staphylococcei
UA95646C2 (ru) Вакцина, которая включает адъювант на основе эмульсии масло-в-воде
NZ611463A (en) Inactivated dengue virus vaccine with aluminium-free adjuvant

Legal Events

Date Code Title Description
FC Refusal